Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma

Journal of Ocular Pharmacology and Therapeutics

Volumn 30, Issue 5, 2014, Pages 429-439

  Yanochko, Gina M ^a   Affolter, Timothy ^a   Eighmy, Johnnie J ^b   Evans, Mark G ^a   Khoh Reiter, Su ^a   Lee, Dong ^a   Miller, Paul E ^c   Shiue, Michael H I ^a   Trajkovic, Dusko ^a   Jessen, Bart A ^a  

^a PFIZER INC   (United States)

^b 206 Carnegie Center   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CP 544326; CYTOKINE; DRUG METABOLITE; INTERLEUKIN 6; PF 04996049; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; TAPRENEPAG ISOPROPYL ESTER; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CORNEA ENDOTHELIUM; CORNEA EPITHELIUM; CORNEA THICKNESS; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; EYE; EYE TOXICITY; GLAUCOMA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTRAOCULAR PRESSURE; IRITIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MONOCYTE; NONHUMAN; PROCEDURES; WESTERN BLOTTING; AGONISTS; ANIMAL; BOVINAE; CELL CULTURE; DOG; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; MACACA FASCICULARIS; MALE; PATHOLOGY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; TRENDS;

ACETATES; ADMINISTRATION, OPHTHALMIC; ADMINISTRATION, TOPICAL; ANIMALS; CATTLE; CELLS, CULTURED; DOGS; DRUG DISCOVERY; EPITHELIUM, CORNEAL; GLAUCOMA; HUMANS; MACACA FASCICULARIS; MALE; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84902131257     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2013.0222     Document Type: Article

References (22)

1. Schachar, R.A., Raber, S., Courtney, R., and Zhang, M. A Phase 2, randomized, dose-response trial of Taprenepag Isopropyl (PF-04217328) versus Latanoprost 0.005% in open-Angle glaucoma and ocular hypertension. Curr. Eye Res. 36:809-817, 2011
2. Prasanna, G., Carreiro, S., Anderson, S., et al. Effect of PF-04217329 a prodrug of a selective prostaglandin EP2 agonist on intraocular pressure in preclinical models of glaucoma. Exp. Eye Res. 93:256-264, 2011
3. Khoh-Reiter, S., and Jessen, B.A. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol. 9:5, 2009
4. Yanochko, G.M., Khoh-Reiter, S., Evans, M.G., and Jessen, B.A. Comparison of preservative-induced toxicity on monolayer and stratified Chang conjunctival cells. Tox. In Vitro. 24:1324-1331, 2010
5. Chomorat, P., Banchereau, J., Davoust, J., and Palucka, A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 1:510-514, 2000
6. Peterson, J.A., Tian, B., McLaren, J.W., Hubbard, W.C., Geiger, B., and Kaufman, P.L. Latrunculin's effects on intraocular pressure, aqueous humor flow and corneal endothelium. IOVS. 41:1749-1758, 2000
7. Edelhauser, H.F. The balance between corneal transparency and edema. IOVS. 47:1755-1767, 2006
8. Schachar, R.A., Raber, S., Thomas, K.V., Benetz, B.A.M., Szczotka-Flynn, L.B., Zhang, M., Howell, S.J., and Lass, J.H. Subclinical increased anterior stromal reflectivity with topical taprenepag isopropyl. Cornea. 32:306-312, 2013
9. Russo, A., Riva, I., Pizzolante, T., Noto, F., and Quaranta, L. Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: A review. Clin. Ophthalmol. 2:897-905, 2008
10. Biswas, S., Bhattacherjee, P., and Paterson, C.A. Prostaglandin E2 receptor subtypes, EP1, EP2, EP3 and EP4 in human and mouse ocular tissues-A comparative immunohistochemical study. Prostaglandins Leuokot. Essent. Fatty Acids. 71:277-288, 2004
11. Bonnano, J.A. Identity and regulation of ion transport mechanisms in the corneal endothelium. Prog. Ret Eye Res. 22:69-94, 2003
12. Parikh, C.H., and Edelhauser, H.F. Ocular surgical pharmacology: Corneal endothelial safety and toxicity. Curr. Opin. Ophthalmol. 14:178-185, 2003
13. Regan, J.W. EP2 and EP4 receptor signaling. Life Sci. 74:143-153, 2003
14. Wigham, G.G., Turner, H.C., Swan, J. and Hodson, S.A. Modulation of corneal endothelial hydration control mechanisms by Rolipram. Pflügers Arch. Eur. J. Physiol. 440: 866-870, 2000
15. Shivanna, M. and Srinivas, S.P. Elevated cAMP opposes TNF-A-induced loss in the barrier integrity of corneal endothelium. Mol. Vision. 16:1781-1790, 2010
16. Riley, M.V., Winkler, B.S., Starnes, C.A., and Peters, M.I. Adenosine promotes regulation of corneal hydration through cyclic adenosine monophosphate. IOVS. 37:1-10, 1996. (Pubitemid 26036511)
17. Kozawa, O., Suzuki, A., Tokuda, H., Kaida, T., and Uematsu, T Interleukin-6 synthesis induced by prostaglandin E2: Cross-Talk regulation by protein kinase C. Bone. 22:355-360, 1998
18. Tavakoli, S., Cowan, J., Benfield, T., Logun, C., and Shelhamer, J.H. Prostaglandin E2-induced interleukin-6 release by a human airway epithelial cell line. Am. J. Physiol. Lung Cell. Mol. Physiol. 280:L127-L133, 2001
19. Raychaudhuri, N., Douglas, R.S., and Smith, T.J. PGE2 induces IL-6 in orbital fibroblasts through EP2 receptors and increased gene promoter activity: Implications to thyroid-Associated ophthalmopathy. PLoS One. 5:e15296, 2010
20. Wang, P., Zhu, F., and Konstantopoulos, K. Prostaglandin E2 induces interleukin-6 expression in human chondrocytes via cAMP/protein kinase A-And phosphatidylinositol 3-kinase-dependent NF-kB activation. Am. J. Physiol. Cell Physiol. 298:C1445-C1456, 2010
21. Zeng, L., An, S., and Goetzl, E.J. EP4/EP2 receptor-specific prostaglandin E2 regulation of interleukin-6 generation by human HSB.2 early T cells. J. Pharm. Exp. Ther. 286:1420-1426, 1998
22. Ikegami, R., Sugimoto, Y., Segi, E., Katsuyama, M., Karahashi, H., Amano, F., Maruyama, T., Yamane, H., Tsuchiya, S., and Ichikawa, A. The expression of prostaglandin E receptors EP2 and EP4 and their different regulation by lippolysaccharide in C3H/HeN peritoneal macrophages. J. Immunol. 166:4689-4696, 2001.